Share Name Share Symbol Market Type Share ISIN Share Description
E-Therapeutics LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 9.25p 9.00p 9.50p 9.25p 9.25p 9.25p 10,592 07:51:52
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.3 -3.3 - 24.83

E-Therapeutics (ETX) Latest News

More E-Therapeutics News
E-Therapeutics Takeover Rumours

E-Therapeutics (ETX) Share Charts

1 Year E-Therapeutics Chart

1 Year E-Therapeutics Chart

1 Month E-Therapeutics Chart

1 Month E-Therapeutics Chart

Intraday E-Therapeutics Chart

Intraday E-Therapeutics Chart

E-Therapeutics (ETX) Discussions and Chat

E-Therapeutics Forums and Chat

Date Time Title Posts
20/9/201607:10ETX-Fighting MRSA & winning.136
18/5/201310:49ETX : Stocktube Vid74
23/7/201123:22ETX, The Boss & the Company-

Add a New Thread

E-Therapeutics (ETX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all E-Therapeutics trades in real-time

E-Therapeutics (ETX) Top Chat Posts

E-Therapeutics Daily Update: E-Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ETX. The last closing price for E-Therapeutics was 9.25p.
E-Therapeutics has a 4 week average price of 9.24p and a 12 week average price of 10.90p.
The 1 year high share price is 29.25p while the 1 year low share price is currently 8.88p.
There are currently 268,389,125 shares in issue and the average daily traded volume is 3,958 shares. The market capitalisation of E-Therapeutics is £24,825,994.06.
dynoport: Eh? can anyone decipher this?
curriedquaker: At least the RNS didn't say that the company had no idea why there is a recent rise in its share price. All it did was reiterate what has already been communicated. Hopefully the press will make a comment tomorrow morning and we'll see if this continues upwards or the profit taking will take hold
127tolmers: 26 February 2015, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, notes the recent rise in its share price and confirms the following. The Company has continued to observe high levels of productivity through the application of its proprietary drug discovery processes, finding a large number of highly active molecules in cellular screens for molecules selected by the discovery platform, as was noted in the RNS issued on 27 November 2014. e-Therapeutics believes that this yield of active compounds represents a proportion of those screened that is several orders of magnitude higher than the published ranges observed in conventional drug discovery processes. The Company believes this enrichment reflects the utility of using its proprietary approach to network science and chemical biology to enhance the selection of molecules that are likely to be attractive for further development. The Company continues to focus its discovery team on generating a substantial number of strong candidate molecules across several disease areas. Discovery and development activity at the Company otherwise continues in line with stated plans and the Company intends to provide a further update in its full year results for the year ended January 2015, expected to be released on 31 March 2015.
dynoport: the product seems to work! affect on share price?
leedsu36: Here try this.... DRUG discovery and development company e-Therapeutics recorded a steep rise in its share price after announcing positive progress in several drugs trials in its preliminary results. The AIM-listed company, based in Newcastle, reported growing momentum in key areas of the business, prompting shares to rise 12.5% to close at 33.75p, despite noting full-year net losses of £4.2m, up from £3.2m. The company's year-end cash and liquid resources of £9.8m at January 31, 2013, have now been boosted to £48m after its March shares placing, money which will allow it to increase investment in research and development. Together with expected receipts from R&D tax credits and interest, the resources are intended to support all of the company's currently planned discovery and development activities into 2017. At that point, the directors hope to have made an out-licensing deal for its most important drug, the cancer drug known as ETS2101, which will have £25m pumped into its development. The Newcastle University spin-out company started clinical trials in the UK – including the Sir Bobby Robson Cancer Trials Research Centre in Newcastle – and US for the cancer drug. Both trials have a dose-escalating design, in which groups of patients receive increasing doses in a bid to discover the best way to administer it, and having received relatively low dose levels no serious adverse reactions were recorded. In the lab, the drug was found to be able to kill off all types of cancer, yet it is not known how well it will work in human trials so it is now being tested on people with all forms of solid tumours. Chief executive Prof Malcolm Young said e-Therapeutics was the fourth highest riser on AIM after issuing its results – evidence that investors are taking an interest in the company's progress. He added: "We've got a large amount of money – around £50m to £60m – to deploy between now and 2017, so we are definitely sitting pretty financially. "And in terms of progress of assets, we know that the lead cancer drug is pharmacologically active in man, and with the anti-depressant drug the discovery team is moving on further." The firm currently employs 17 people, with more becoming involved during trials, and there is scope for more job creation. Prof Young said: "We will potentially take more people on, but it won't be a step change. "I often ask myself the £50bn question – what would I do if we had £50bn in the bank instead of £50m, and would we be doing things differently, and the answer is not radically, no."
leedsu36: You might like this then B1, Commenting on the results, Professor Malcolm Young, chief executive officer of e-Therapeutics, said: "We have growing momentum in the key areas of our business. Use of our innovative network pharmacology platform to discover new drugs is on track while our most significant product candidate, the cancer drug ETS2101, is making good progress in the clinic." The share price advanced 15% to 34.4 pence, valuing the Newcastle-based group at £48mln. However City broker Panmure Gordon believes the stock has further to go as tweaked its target 3 pence higher to 70 pence a share. Analyst Savvas Neophytou said: "We had been anticipating safety data from the company's lead product candidate ETS2101 in the fourth quarter. "Therefore it was a positive surprise to hear today's announcement of strong success in the treatment of one particular patient whose tumour was greatly reduced in size. "This sector is not used to success so the pessimists will scream sample size, chance event and other such instruments of caution. "They would be right from a purist point of view but the fact remains one particular patient who had ran out of all therapeutic options is still alive as a result of ETS2101 and that is a significant achievement for the company's first shot at goal."
ezlington: What I did with this vid : was to watch it about 4 times. Googled important terms and checked the top relevant links (blind alleys excluded): eg: network pharmacology: (The future of small molecule ligands) Drug development cycle: Phase 2 (two, ii , II) trials View the basic financials : Check other online sources, , TMF, ADVFN, III, Bloomberg, Yahoo, ETC. Re-watch vid about 2 times. Listen to vid with screen off, listening intently to certain phrases Note phrase & time of phrases! "Two assets to sweat" 2.03 Network Platform (nothing for 10 years still to busy) { BTLines : HUGE POTENTIAL} Developing Assets 2.22 : (5 Ph II drugs @ £200m each, current focus of business : 2min.35 sec) Nett Potential Value (Industry standard valuations @ end of Phase II) of £200m per drug 3min.14 Watch vid with sound off watching intently for significant body language signs: These are interpretational, eye contact, physical contact, smile, type of smile, tone of voice with accompanying dialogue, etc, all influence interpretation. The Smile : I thought the most significant was when he was questioned about a float on the USA stock market or a potential US take-over, see and 3.16 predicted £200m valuation , "yeah, I agree!" 3.27 : 2.9 M cash, burn rate of 1.9m = £1M & £16.6M RAISED so why raise the cash when you do not need it? My guess: They have had a research request from a major pharma who wants ETX to run their prospective drugs through their platform and need the cash to build the facility. 3min 35smug hand clasp over burn rate : "I know this, watch me impress him" (notice shrug!) 3.38.."We have pre paid for 125 patients.." This is saying that Phase II trials are almost in the final stages, why else would you pre-pay? If you pre pay, you know the results! Phase II is over and what did he say about that? 5.50 -5.55 ..."and then redeeming that value" also the phrase "unequivocally demonstrated" Sounds like £200m coming our way soon! The quoted industry standard value was AROUND £200m/$320M (2.22)(HAVE THEY SOLD A DRUG THAT HAS COMPLETED PHASE II?) Focussed on the assets (5 Phase II drugs which will be sold on completion) 2min27 " we have moved ...pretty much all our resources to develop these assets" Discovery platform First mention of engaging with other companies to fast track their potential drug molecules 2.38: "To engage with MUCH LARGER companies discovery programmes". 3.55 "reasonably unlikely" that "(not) any body paying us for anything" Well, cutting this short, What are the potential areas of news/announcements? 1. Phase II Trials are progressing well. One Phase II Trials is almost complete. One Phase II Trials is almost complete and we are in negotiations One Phase II Trials is complete and we have been offered £200m 2. Our Patented platform that screens drug molecule binding sites on proteins (to predict unwanted effects) Is discovering new drugs Is successfully screening potential drug molecules, under long term contract, for Glaxo, Astra & Phizer Is highly cash generative 3. Following our maiden Phase II sale, the transformational revenue stream from the platform and the AIM markets historical disinterest in our shares, a NASDAQ floatation is being persued to address share price under performance. What are the likely areas of news/announcements? Cash is being generated by screening potential drug molecules for other companies. One Phase II Trials is almost complete. Two other Phase II Trials are abandoned (hey, chit happens!). NASDAQ floatation is likely. This share rarely moves in price due to very low volume. Any good news could have a disproportionate effect on the price ETX is a small £50m company with  87.8% of its shares with institutional investors. The share has been remarkably stable since the re-rating (24 - 36p) in February, largely because insiders and loyal shareholders have high hopes for this company and it has not yet reached the stage of making ground breaking transformational announcements. Lets see what Monday brings. From RNS 29 June: Notice of Preliminary Results e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will be announcing its final results for the 12 month period ending 31(st) January 2011 on Monday 25(th) July 2011. Professor Malcolm Young, CEO, Daniel Elger, CFO, and Stephen Self, Development Director, will be hosting a presentation for analysts at 9.30am on the morning of the results at the offices of College Hill, The Registry, Royal Mint Court, EC3N 4QN. (hope there is a vid of the presentation on the website!)
ezlington: ETX, The Boss & the Company Who is Stephen Self? Mr. Stephen Raymond Self, Steve serves as Development Director of e-Therapeutics plc. Mr. Self began his career in Chemistry in 1975 with The Wellcome Foundation. He held a variety of positions in both R&D and Operations before being appointed as a full-time Project Manager in Wellcome Research in 1987. He became Head of Project management in 1991, and was appointed Group Vice President of Project Management in 1993. He joined Boots Healthcare International in 1995 as Head of Respiratory and Analgesic product development, before joining Merck Generics in 1997 as European Technical Director. He served as Group R&D Director of Merck Generics since 1999 and stayed with Merck until its sale to Mylan in 2007. Since then he has worked for a private equity bank on major US pharmaceutical acquisitions. Mr. Self has been an Executive Director of e-Therapeutics plc since December 2010. An impressive career. What are his Directors' Dealings " Definition Purchase or sale of a firm's shares by its director(s), usually prohibited during certain times of the year (such as a certain number of weeks preceding the declaration of annual figures) because the directors are deemed to know more about the firm's prospects than anybody else. For the same reason, directors' dealings often attract more attention by the financial press than the outsiders' dealings." This is well illustrated by Mr Self's dealings, a persistent buyer in the companies shares until 16 weeks before the annual results. Obviously Mr self has confidence in the future of this Company!  Steve Self, an Executive Director, purchased on the   10 March 2011 26,677 ordinary shares at 37.5p per share. His resultant total holding is 113,090 shares representing 0.08% of the issued share capital of the company Steve Self, an Executive Director, purchased on the 15 March 2011 50,000 ordinary shares at 36.5p per share. His resultant total holding is 163,090 shares representing 0.11% of the issued share capital of the company  Steve Self, an Executive Director, purchased on 18 May 2011 20,189 ordinary shares at 36.9p per share. His resultant total holding is 183,279 shares representing 0.13% of the issued share capital of the company  Mr. Self purchased 13,698 ordinary shares on 7 April 2011, at 36.5 pence per share These shares were all purchased more than 10 p above the recent institutional purchases and at a price close to the 36.64p that I paid for them on Friday. Current Holding 196,977 ordinary shares (representing 0.14% of the issued share capital) His Options:  option awards granted at the time of his appointment.  -  options whereby he is entitled to acquire, at par value, up to 500,000 new ordinary shares of 0.1 pence each in the Company (the "Options"); -  the Options may only be exercised within a six-month period following the third anniversary of its grant provided that the Company's share price at that third anniversary is not less than 100 pence; -  the Options may be exercised sooner in the event of a change of control, but only if the price offered by the person acquiring control of the Company at least 67 pence per share; -  at the same time, a further award of options was made to Mr. Self, for which the commencement of its three-year vesting period is conditional on his continuing to be employed by the Company on the first anniversary of the award (the "Conditional Options"); -  the Conditional Options represent an entitlement to buy, at par value, up to a further 350,000 new ordinary shares of 0.1 pence each in the Company; -  the Conditional Options are exercisable on a similar basis to the option described above, save the option may only be exercised following the fourth anniversary of the conditional award. As options go, these are "shareholder friendly" not excessive in any way and if the share price is £1.00 in three years I would not be complaining. So what does ETX Do? Rather than quote the website, Bloomberg says e-Therapeutics plc engages in the discovery and development of drugs using its proprietary network analysis technology primarily in the United Kingdom. The company provides drug candidates in areas of oral asthma, depressive disorder, topical MRSA, metastatic cancer, fibromyalgia, atherosclerosis, clostridium difficile, and IV MRSA. Its drug candidates include ETX9101 used for oral asthma medication; ETS6103, an analgesic antidepressant candidate; ETX1153b, a small molecule candidate for dangerous resistant gram-positive infections, such as MRSA, VRSA, and VRE; and ETS2101, a selective apoptotic for various types of malignant cancer. The company's drug candidates also comprise ETX6218, a combination of candidate of two reprofiled compounds for the treatment of Fibromyalgia; ETX6107, a candidate for the treatment of atherosclerosis; ETX1153c, a small molecule candidate for C.difficile; and ETX1153a, a drug candidate for hospital-based infections caused by dangerous resistant gram-positive bacteria. It has a collaboration agreement with Infinitus Clinical Research Limited, as well as a partnership agreement with Khandelwal Laboratories Pvt Limited. What about the Money side of ETX? Like most small research Pharm. Companies it has a "burn rate" IE : it is living off it's capital, Historically this has been -2m ,-1.5m & -1.8m in the last 3 years. As the number of ongoing projects has changed and the stage of their development has advanced it is top be expected that the loss will increase in this years results. I would not be shocked at a burn rate of £4m to reflect this, I would be delighted if there was income for work undertaken for other pharmaceutical companies, no matter how small the number, it would show signs that the sector is beginning to wake up to the potential of ETX's patented methods and a value reflecting how this intellectual property could facilitate rapid drug discovery and the prediction of potential side effects. Since ETX just raised almost £17m in February, that is far more than a "burn rate" buffer. Some other development may be around the corner, new facilities? Clinical trials? Expansion of staff etc. really nice would be moves to get ETX1153 FDA Approval? ETX is a small £50m company with  87.8% of its shares with institutional investors. The share has been remarkably stable since the re-rating in February, largely because insiders and loyal shareholders have high hopes for this company and it has not reached the stage of making ground breaking transformational announcements. Lets see what tomorrow brings. Read the website ADYOR
windass: Extract from report by GE&CR - 106p target price e-Therapeutics is an AIM listed UK based drug discovery company targeting therapeutic sectors with high unmet clinical using its unique and fully patented in silico bio-analytics drug discovery platform. The company, through this platform, has a growing portfolio of repositioned and proprietary drug candidates progressing to Phase II clinical trials. in silico ticks three of the key boxes for any major pharmaceutical company. It potentially reduces the risk of candidate failure and the time to market (i.e. extending the candidates patent life) through the application of its unique bio-analytics algorithms. (For example, the conventional drug discovery approach typically takes 15 years before a candidate reaches the market while e-Therapeutics can reduce this to 8 years for a new chemical entity and 6 years for a repositioned candidate.) More importantly, the in silico platform's algorithm's can analyse complex biological systems and diseases and generate potential candidates for their successful treatment. e-Therapeutics is commercially focused and recognised that the quicker commercial successes will come from reprofiling existing drug candidates, using its in silico technology, to meet new unmet clinical needs and thereby generate earlier revenue stream. This is the basis of their own proprietary portfolio of candidates to date. The company de-risked the investment risk through a placing in February, raising £17.6 million before expenses of development capital at 26p per share, which should see the company through to full commercialisation of its existing pipeline of candidates. Realistically valuing any early biopharma is, to say the least, highly speculative because they are typically bets on one or two very early stage drug candidates ever making it to market or securing a late stage clinical trial partner before the company runs out of cash. However, e-Therapeutics is unlike its stereotypical peers because it has a unique, patented, bio-analytical drug discovery platform ( in silico ) that has already generated a sizeable, diversified and growing portfolio of drug candidates that are targeted upon commercially large areas of unmet clinical need. Indeed, some of the portfolio has already been part licensed. Nevertheless, we have decided to value, or more accurately provide, an indication of the potential value for this pre-revenue company, using very cautious assumptions for only 3 of its current portfolio of 8 drug candidates for the period 2014 - 2028 These candidates have a combined addressable potential market of US$76.5 billion. Our heavily risk discounted NPV generates an indicative share price of 106p rising to 423p if the 3 candidates are successful in their forthcoming Phase II trials. Neither figure attributes any value to the unique and fully patent protected drug candidate development platform in silico, which should become increasingly more valuable as the portfolio expands and more candidates become partnered. Obviously, realisation of any potential value is dependent upon many variables but between now and the first commercial launches estimated to be during 2014/15, we anticipate that the share price will respond more to news flow concerning the results of clinical trials for these candidates, and the other portfolio candidates, as well as, development partner announcements. Consequently, we recommend the shares as a buy at 37p with a 106p target price.
aim_trader: e-Therapeutics Phase II drugs could have a £1bln potential value for the company Monday, September 13, 2010 Malcolm Young, CEO of e-Therapeutics talks to Proactive Investors on the potential value of drugs in Phase II of the pipeline and that there's a disconnect between the share price and the value of the science owned by the company. He says, in general terms, there's a better understanding of biotech companies in the US than there is in the UK, an obvious reason to keep an eye on the US markets.
E-Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161022 13:34:10